Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rhythm Pharmaceuticals (RYTM) Long-Term Investments (2021 - 2025)

Historic Long-Term Investments for Rhythm Pharmaceuticals (RYTM) over the last 5 years, with Q3 2025 value amounting to $2.5 million.

  • Rhythm Pharmaceuticals' Long-Term Investments fell 7937.79% to $2.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.5 million, marking a year-over-year decrease of 7937.79%. This contributed to the annual value of $7.3 million for FY2024, which is 5115.67% down from last year.
  • Latest data reveals that Rhythm Pharmaceuticals reported Long-Term Investments of $2.5 million as of Q3 2025, which was down 7937.79% from $2.2 million recorded in Q2 2025.
  • Rhythm Pharmaceuticals' 5-year Long-Term Investments high stood at $18.4 million for Q1 2022, and its period low was $2.2 million during Q2 2025.
  • In the last 5 years, Rhythm Pharmaceuticals' Long-Term Investments had a median value of $13.8 million in 2024 and averaged $12.3 million.
  • In the last 5 years, Rhythm Pharmaceuticals' Long-Term Investments skyrocketed by 4825.79% in 2022 and then crashed by 8258.82% in 2025.
  • Rhythm Pharmaceuticals' Long-Term Investments (Quarter) stood at $11.8 million in 2021, then soared by 40.96% to $16.7 million in 2022, then fell by 9.94% to $15.0 million in 2023, then crashed by 51.16% to $7.3 million in 2024, then tumbled by 66.24% to $2.5 million in 2025.
  • Its last three reported values are $2.5 million in Q3 2025, $2.2 million for Q2 2025, and $7.1 million during Q1 2025.